Sinovac Receives Commercial Approval in Mexico for Seasonal Flu Vaccine

   Sinovac Receives Commercial Approval in Mexico for Seasonal Flu Vaccine

PR Newswire

BEIJING, April 18, 2013

BEIJING, April 18, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq:SVA), a
leading provider of vaccines in China, announced today that it has received
the Certificate of Approval to commercialize seasonal flu vaccine in Mexico by
the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) of
the Mexico Ministry of Health. The certificate of commercial approval is valid
from April 1, 2013 to April 1, 2018. The Company filed the application to
distribute Anflu inMexico in 2005, and received the GMP certificate for its
seasonal flu and hepatitis A vaccines on August 11, 2011.

Laboratorios Imperiales S.A. de C.V., a biopharmaceutical company operating
inMexicosince 1935, is the exclusive distributor of Sinovac's vaccine
products in Mexico, pursuant to a distribution agreement signed in 2005 with
its affiliate.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, said, "This is a
great milestone for Sinovac as we look to continue expanding our commercial
efforts worldwide. We are pleased to receive approval to supply Anflu in the
Mexican market, which we perceive as a significant opportunity outside of
China. We expect to begin sales planning for Mexican market in conjunction
with our partner, Laboratorios Imperiales, in the coming days."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on research, development, manufacturing and commercialization of vaccines that
protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal
rabies vaccine. In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for
the Chinese Central Government, pursuant to the government-stockpiling
program.The Company is also the only supplier of the H5N1 pandemic influenza
vaccine to the government-stockpiling program. Sinovac is developing a number
of new pipeline vaccines including vaccines for enterovirus 71 (against hand,
foot, and mouth disease), pneumococcal conjugate, pneumococcal
polysaccharides, varicella and rubella.Sinovac sells its vaccines mainly in
China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Sinovac was also granted a license to commercialize seasonal flu vaccine in
Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

CONTACT:

Helen Yang
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com



SOURCE Sinovac Biotech Co., Ltd.